Scores highest PAT of Rs 118 in FY25
Morepen Laboratories board has proposed to declare a dividend (Rs 0.20 per share) after a gap of 23 years, marking a defining moment in the company’s four-decade legacy, subject to approval of the shareholders in the forthcoming Annual General Meeting.
The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 1,830 crore, up from Rs 1,704 crore in FY24 — a 7.4 per cent year-on-year increase. EBITDA surged 21.6 per cent to Rs 118 crore, and Profit After Tax jumped to Rs 118 crore, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.
Sushil Suri, CMD, Morepen Laboratories, said, “This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”
Morepen’s API business continued to dominate, contributing Rs 989 crore, while the medical devices segment surged to Rs 496 crore, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.
